SYRE insider transactions
Spyre Therapeutics Inc. (SYRE) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
SYRE insiders
Everyone who has filed a Form 3, 4, 5 or 144 at Spyre Therapeutics Inc., latest first. Follow anyone to get their next filing.
- Cameron TurtleChief Executive Officer, Director, since June 2023-$11.4M
- Heidy King-JonesOfficer, since September 2023-$5.11M
- Scott L BurrowsChief Financial Officer, since September 2023-$9.95M
- Jeffrey W. AlbersDirector, since November 2023-$2.66M
- Sheldon SloanChief Medical Officer, since October 2024-$7.35M
- Fairmount Funds Management LLCDirector, since June 2023-$400M
- Michael Thomas HendersonDirector, since June 2023-$7.95M
- Laurie StelzerDirector, since November 2023
- Mark C. McKennaDirector, since February 2024
- Sandra MilliganDirector, since May 2024
- Jonathan AlspaughOfficer, since July 2021+$605K
- Russell J. CoxDirector
- Ivana Magovcevic-LiebischDirector
- Hunter C SmithDirector, since November 2021
- Alison Frances LawtonDirector
- Linda L NeumanOfficer, since November 2022
- James Paul KastenmayerOfficer, since August 2022
- Hanley Jr. Michael ConickOfficer+$20K
- Jeff Marc GoldbergOfficer, Director, since November 2022
- Marcio SouzaDirector, since June 2021+$50.5K
- Leslie SloanOfficer
- Armen ShanafeltDirector+$550K
- Sandesh MahatmeDirector
- V Bryan LawlisDirector
- Anthony G. QuinnOfficer, Director+$668K
- Steven WeberOfficer, since February 2021
- Baker Bros. Advisors LPDirector, since February 2021
- Sara BrownsteinDirector, since February 2021
Recent Form 3, 4, and 5 filings for SYRE
- Officer King-Jones Heidy exercised 28,933 shares at a strike of $14.50 and sold $2,633,902 worth of shares (28,933 units at $91.03) as part of a pre-agreed trading plan (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Chief Executive Officer Turtle Cameron sold $1,380,105 worth of shares (15,000 units at $92.01) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 537,540 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Chief Financial Officer Burrows Scott L exercised 25,000 shares at a strike of $14.50 and sold $2,261,831 worth of shares (25,000 units at $90.47) as part of a pre-agreed trading plan (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Officer King-Jones Heidy exercised 28,399 shares at a strike of $14.50 and sold $2,480,529 worth of shares (28,399 units at $87.35) as part of a pre-agreed trading plan (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Chief Financial Officer Burrows Scott L exercised 7,500 shares at a strike of $14.50 and sold $2,283,821 worth of shares (25,732 units at $88.75) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 79,762 units (SEC Form 4) (for tax liability)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Chief Executive Officer Turtle Cameron sold $1,309,410 worth of shares (15,000 units at $87.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 552,540 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Director Albers Jeffrey W. exercised 5,000 shares at a strike of $10.39 and sold $2,404,190 worth of shares (23,000 units at $104.53) as part of a pre-agreed trading plan (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Chief Financial Officer Burrows Scott L exercised 7,500 shares at a strike of $14.50 and sold $716,771 worth of shares (7,500 units at $95.57) as part of a pre-agreed trading plan (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Chief Executive Officer Turtle Cameron sold $1,432,705 worth of shares (15,000 units at $95.51) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 567,540 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Chief Financial Officer Burrows Scott L exercised 7,500 shares at a strike of $14.50 and sold $658,040 worth of shares (7,500 units at $87.74) as part of a pre-agreed trading plan (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Chief Medical Officer Sloan Sheldon exercised 8,334 shares at a strike of $27.46 and sold $730,896 worth of shares (8,334 units at $87.70) as part of a pre-agreed trading plan (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Chief Executive Officer Turtle Cameron sold $1,315,346 worth of shares (15,000 units at $87.69) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 582,540 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Chief Financial Officer Burrows Scott L exercised 15,000 shares at a strike of $14.50 and sold $1,307,000 worth of shares (15,000 units at $87.13) (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Director Fairmount Funds Management Llc converted options into 666,680 shares and sold $399,658,667 worth of shares (4,684,781 units at $85.31) (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Director Henderson Michael Thomas sold $2,000,000 worth of shares (20,000 units at $100.00) as part of a pre-agreed trading plan, decreasing direct ownership by 23% to 68,606 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Chief Medical Officer Sloan Sheldon exercised 8,333 shares at a strike of $27.46 and sold $624,975 worth of shares (8,333 units at $75.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Chief Executive Officer Turtle Cameron sold $1,056,486 worth of shares (15,000 units at $70.43) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 597,540 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Chief Financial Officer Burrows Scott L sold $532,937 worth of shares (7,500 units at $71.06) as part of a pre-agreed trading plan and exercised 7,500 shares at a strike of $14.50 (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Director Fairmount Funds Management Llc4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Director Albers Jeffrey W.4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Director Henderson Michael Thomas4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Director Stelzer Laurie4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Director Mckenna Mark C.4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Director Milligan Sandra4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Director Henderson Michael Thomas sold $5,952,050 worth of shares (80,000 units at $74.40) as part of a pre-agreed trading plan, decreasing direct ownership by 47% to 88,606 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Chief Financial Officer Burrows Scott L exercised 12,500 shares at a strike of $14.50 and sold $892,125 worth of shares (12,500 units at $71.37) as part of a pre-agreed trading plan (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Chief Medical Officer Sloan Sheldon exercised 78,333 shares at a strike of $27.46 and sold $5,600,701 worth of shares (78,333 units at $71.50) as part of a pre-agreed trading plan (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Chief Executive Officer Turtle Cameron sold $1,070,507 worth of shares (15,000 units at $71.37) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 612,540 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Turtle Cameron4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Sloan Sheldon4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Burrows Scott L4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Chief Financial Officer Burrows Scott L exercised 2,500 shares at a strike of $14.50 and sold $101,620 worth of shares (2,500 units at $40.65) (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Chief Executive Officer Turtle Cameron sold $632,866 worth of shares (15,000 units at $42.19), decreasing direct ownership by 2% to 642,540 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Chief Executive Officer Turtle Cameron sold $492,045 worth of shares (15,000 units at $32.80), decreasing direct ownership by 2% to 657,540 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Director Henderson Michael Thomas acquired 63,227 shares, increasing direct ownership by 60% to 168,606 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Burrows Scott L4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Chief Executive Officer Turtle Cameron4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Chief Medical Officer Sloan Sheldon4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Officer King-Jones Heidy4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Chief Executive Officer Turtle Cameron sold $460,134 worth of shares (15,000 units at $30.68), decreasing direct ownership by 2% to 671,907 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Chief Executive Officer Turtle Cameron sold $435,356 worth of shares (15,000 units at $29.02), decreasing direct ownership by 2% to 686,907 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Chief Executive Officer Turtle Cameron sold $1,049,778 worth of shares (45,000 units at $23.33), decreasing direct ownership by 6% to 701,907 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Chief Financial Officer Burrows Scott L sold $299,639 worth of shares (18,428 units at $16.26), decreasing direct ownership by 16% to 97,994 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Director Fairmount Funds Management Llc4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Director Stelzer Laurie4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Director Milligan Sandra4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Director Mckenna Mark C.4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Director Henderson Michael Thomas4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Director Albers Jeffrey W.4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Burrows Scott L4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Chief Medical Officer Sloan Sheldon4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Chief Executive Officer Turtle Cameron4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Officer King-Jones Heidy4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Director Henderson Michael Thomas acquired 105,379 shares (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Director Albers Jeffrey W. sold $246,313 worth of shares (6,700 units at $36.76) (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Director Albers Jeffrey W. sold $10,929 worth of shares (300 units at $36.43) (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Chief Medical Officer Sloan Sheldon4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 3 filed by new insider Sloan Sheldon3 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- Chief Financial Officer Burrows Scott L sold $522,074 worth of shares (18,531 units at $28.17), decreasing direct ownership by 14% to 116,422 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- SEC Form 4 filed by Albers Jeffrey W.4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)